Treatment Pathways for AIHA: Choosing the Right Road

Once your subtype of Autoimmune Hemolytic Anemia (AIHA) is confirmed, your medical team will choose a treatment “roadmap.” It is vital to understand that the path for Warm AIHA (wAIHA) and Cold Agglutinin Disease (CAD) are almost entirely different. A treatment that is a “gold standard” for one may be completely ineffective for the other ^[1][2].

Essential Supportive Care: Folic Acid

Regardless of your subtype, your bone marrow has to work overtime to replace the red blood cells being destroyed. This rapid production quickly depletes your body’s stores of folate. Without daily folic acid supplementation, your bone marrow could run out of fuel, bringing red blood cell production to a complete halt (a “megaloblastic crisis”) ^[3]. Taking a daily folic acid supplement is a standard part of AIHA management.

Treatment Pathway for Warm AIHA (wAIHA)

In wAIHA, the goal is to stop the spleen from destroying red blood cells and to “quiet” the immune system.

• First-Line: Corticosteroids (Prednisone)
  • Steroids are the initial standard of care for nearly all patients with wAIHA ^[4][5]. They work by rapidly reducing the production of autoantibodies. While effective, they are rarely a long-term solution due to significant side effects. You and your doctor must monitor for short- and long-term effects, including blood sugar spikes, severe mood changes, insomnia, increased risk of infection, and bone density loss (osteoporosis) ^[6].
• Second-Line: Rituximab vs. Splenectomy
  • Rituximab: This is now the preferred second-line choice ^[2][7]. It is a medication given by IV that specifically targets the B-cells responsible for making autoantibodies. It is often chosen over surgery because it is less invasive and avoids the lifelong infection risks associated with not having a spleen ^[8].
  • Splenectomy: Removing the spleen was once the standard second-line treatment. While still effective for some, it is now usually reserved for patients who do not respond to Rituximab ^[2][6].
• Other Immunosuppressants
  • If rituximab is ineffective or unavailable, doctors may use other “steroid-sparing” oral medications—like mycophenolate mofetil, azathioprine, or cyclosporine—to keep the immune system in check over the long term ^[6].

Treatment Pathway for Cold Agglutinin Disease (CAD)

In CAD, the mechanism of destruction is different—it is driven by the complement system rather than the spleen. Because of this, traditional wAIHA treatments do not work.

• Crucial Warning: Steroids and Splenectomy
  • Do not use: High-dose steroids and splenectomy are generally ineffective for CAD ^[1][9]. Steroids would require dangerously high doses to work, and because the destruction doesn’t primarily happen in the spleen, removing it rarely helps ^[10][11].
• First-Line: Rituximab
  • Rituximab (either alone or combined with chemotherapy like bendamustine) is the standard first-line treatment to address the underlying cells making the cold antibodies ^[2][12].
• New Targeted Therapy: Sutimlimab
  • Sutimlimab is a newer, targeted IV therapy specifically for CAD. It works by “flipping a switch” on the complement cascade, stopping the destruction of red blood cells almost immediately ^[13][11]. Critical Safety Warning: Because it blocks a specific part of your immune system, it carries a severe risk of life-threatening infections from encapsulated bacteria. You must receive specific vaccinations (such as for meningococcal disease) before starting this therapy ^[11].
• Essential Lifestyle Change: Cold Avoidance
  • Keeping the entire body warm—not just the hands and feet—is a mandatory part of treatment to prevent the antibodies from “waking up” ^[14].

The Challenge of Blood Transfusions

If your anemia becomes life-threatening, you may need a blood transfusion. However, AIHA makes this complicated:

1. Pan-reactivity: The autoantibodies in your blood often react against all donor blood during testing. This makes the blood look “incompatible” even if it isn’t ^[15].
2. Masking: These “auto” antibodies can hide “allo” antibodies (antibodies you might have developed from previous transfusions or pregnancy), making it hard for the lab to find a safe match ^[16][17].
3. “Least Incompatible” Blood: In emergencies, your doctor may have to authorize a transfusion of “least incompatible” blood. While this sounds scary, it is a standard and necessary practice in AIHA when a perfect match cannot be found ^[15].

Transfusions in AIHA patients must be given slowly and monitored very closely by the medical team ^[16].

Previous: Diagnosis & Lab Reports | Return to Overview | Next: Living with AIHA